Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology

References

• Molica S, Brugiatelli M, Morabito F, et al. Treatment of elderly. patients with chronic lymphocytic leukemia: an unmet clinical need. Exp Rev Hematol 2013;6(4):441-9
   PubMed Web of Science ®Google Scholar
• Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program 2013;2013:158-67
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial [abstract 6]. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; 7 – 10 December 2013; New Orleans, LA, USA
   Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versus chlorambucil alone in Patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract 528]. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; 7 – 10 December 2013; New Orleans, LA, USA
   Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114(16):3382-91
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(26):4378-84
   PubMed Web of Science ®Google Scholar
• Leblond V, Laribi K, Ilhan O, et al. Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study (MaBLe). Results From The Phase 1b Galton Trial (GAO4779g) [abstract 2744]. Program and abstracts of the 54th American Society of Hematology Annual Meeting and Exposition; 8 – 11 December 2012; Atlanta, GA, USA
   Google Scholar
• Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label Phase IIstudy. Blood (ASH Annual Meeting Abstracts) 2010;116:697
   Google Scholar
• Foà R, Giudice ID, Cuneo A, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014. [Epub ahead of print]
   Google Scholar
• Brown JR, O’Brien S, Kingsley CD, et al. Safety and efficacy of obinutuzumab (GA101) with fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of patients with chronic lymphocytic leukemia (CLL): results from the phase 1b galton trial (GAO4779g) [abstract 523]. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; 7 – 10 December 2013; New Orleans, LA, USA
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
   PubMed Web of Science ®Google Scholar
• Foà R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia? N Engl J Med 2013;369(1):85-7
   PubMed Web of Science ®Google Scholar
• A multicenter, open-label, phase 3 study of the bruton’s tyrosine kinase inhibitor pci-32765 versus chlorambucil in patients 65 years or older with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma (RESONATE-2). Clinicaltrials.gov identifier: NCT01722487. Available from: http://clinicaltrials.gov/ct2/show/NCT01722487
   Google Scholar
• A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small Lymphocytic lymphoma. Clinicaltrials.gov identifier: NCT01611090. Available from: http://clinicaltrials.gov/ct2/show/NCT01611090
   Google Scholar
• A phase 3 study of ibrutinib (PCI-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (RESONATE). Clinicaltrials.gov identifier: NCT01578707. Available from: http://clinicaltrials.gov/show/NCT01578707
   Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia: new updated results of a phase II trial in 40 patients [abstract 675]. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; 7 – 10 December 2013; New Orleans, LA, USA
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia [LBA-6]. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; 7 – 10 December 2013; New Orleans, LA, USA
   Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Cheson BD. Available from: www.medscape.com/viewarticle/814736
   Google Scholar
• Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013;122(23):3723-34
   PubMed Web of Science ®Google Scholar